| ADHD Directory |
| ADHD Printables |
| ADHD Webinars |
| ADHD Guides |
| Expert Answers |
| ADHD News |
| Tools and Checklists |
| ADHD Topics A-Z |
| Book Reviews |
 |
| ADHD Groups |
| ADHD Discussions |
| ADHD Blogs |
| Share Your Story |
| E-Newsletters |
| ADHD Events |
| ADHD Videos |
|
| Subscribe |
| Give a Gift |
| Current Issue |
| Digital |
| Archives |
| Buy Back Issues |
| Buy Booklets |
| Customer Service |
| Contact Us |
| Advertise |
No Cancer Risk with ADHD MedsContrary to a previous concerns, new research shows ADHD medications don't increase genetic damage and cancer risk Friday November 21st - 11:57am Filed Under:
ADHD Medication and Children,
Side Effects of ADHD Meds
A new study from Duke University Medical Center and the National Institutes of Health found that two popular medications for treating attention-deficit hyperactivity disorder (ADHD) -- methylphenidate (Ritalin LA and Concerta) and amphetamine (Adderall and Adderall XR) -- do not lead to an increased risk for developing cancer. The study counters a previous one that reported an increase in genetic damage in children taking methylphenidate. The genetic damage is associated with an increased risk of cancer. The new study used a larger sample of children, and did not find increased genetic abnormalities. The study was published in the November online issue of the Journal of the American Academy of Child & Adolescent Psychiatry. Read more about the study.
 |
|
Print
